Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 15/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | CCNC | P24863 | 1/20 | 0.51 |
| ▸ | CDK8 | P49336 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.46 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19349702 | 1.00 | ROCK2 (0.56) | ROCK2DRD2CCNCCDK8GSK3A | |
| SCHEMBL19349704 | 1.00 | ROCK2 (0.56) | ROCK2DRD2CCNCCDK8GSK3A | |
| SCHEMBL19349667 | 0.90 | CCNC (0.58) | ROCK2DRD2CCNCCDK8GSK3A | |
| SCHEMBL17514258 | 0.90 | CCNC (0.58) | ROCK2DRD2CCNCCDK8GSK3A | |
| SCHEMBL17514260 | 0.90 | CCNC (0.58) | ROCK2DRD2CCNCCDK8GSK3A | |
| SCHEMBL17514180 | 0.88 | CCNC (0.59) | ROCK2DRD2CCNCCDK8GSK3A | |
| SCHEMBL19349773 | 0.88 | CCNC (0.59) | ROCK2DRD2CCNCCDK8GSK3A | |
| SCHEMBL17514178 | 0.88 | CCNC (0.59) | ROCK2DRD2CCNCCDK8GSK3A | |
| SCHEMBL17514210 | 0.87 | CCNC (0.59) | ROCK2DRD2CCNCCDK8GSK3A | |
| SCHEMBL17514191 | 0.87 | CCNC (0.59) | ROCK2DRD2CCNCCDK8GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3183239-B1 | INDAZOLES | MERCK PATENT GMBH (DE) | 2018-09-26 | — | — | EP | disclosed |
| US-9862717-B2 | Indazoles | MERCK PATENT GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| US-9862717-B2 | Indazoles | MERCK PATENT GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| US-20170267675-A1 | INDAZOLES | MERCK PATENT GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
| US-20170267675-A1 | INDAZOLES | MERCK PATENT GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
| US-20170267675-A1 | INDAZOLES | MERCK PATENT GMBH (DE) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267675-A1 | INDAZOLES | MKI67, CCNI, BRCA1 | ROCK2 965/4885DRD2 4481/4885CCNC 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.